During the 2021 ASCO Annual Meeting, the Lymphoma Hub spoke with Catherine&nbsp;S.&nbsp;Diefenbach, Perlmutter Cancer&nbsp;Center, New York, US. We asked, What are the recent advances in antibody-drug conjugates for lymphoma treatment?&nbsp; Diefenbach summarizes key safety and efficacy data on three antibody therapies across the histological subtypes of lymphoma. These comprise: polatuzumab&nbsp;vedotin, an anti-CD79 antibody-drug conjugate; the bispecific antibodies mosunetuzumab, glofitamab, and epcoritamab; and finally, tafasitamab, a novel anti-CD19 monoclonal antibody.<hr> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.

Is frontline R-CHOP still the standard of care for DLBCL?

The Lymphoma Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in lymphoma and CLL. Our aim is to enhance knowledge in lymphoma and CLL, through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management. Hosted on Acast. See acast.com/privacy for more information.